After a series of unfortunate regulatory rejections and manufacturing issues surfaced, Regeneron’s shares dipped to $483 this ...

So, Regeneron's revenue rose 1.9% from $3.68 billion in Q2 2025 to $3.75 billion, beating consensus estimate by $160 million ...

Regeneron Pharmaceuticals earns the No. 76 rank among its peers in the Medical-Biomed/Biotech industry group. Exact Sciences ...

In the preceding three months, 15 analysts have released ratings for Regeneron Pharmaceuticals REGN, presenting a wide array of perspectives from bullish to bearish. The table below provides a concise ...

Shares of Regeneron Pharmaceuticals REGN have gained 21.5% year to date compared with the industry’s growth of 10.2%. The ...

Here’s why we believe Regeneron Pharmaceuticals (REGN) stock merits attention as a value addition. Currently, it is trading almost 44% lower than its 1-year peak and is also priced at a PS multiple ...

Biotech giant Regeneron’s (REGN) performance has been pretty ho-hum in the year so far. While Eylea sales continue to be under pressure, affecting the top line, the company finally managed to post ...

Regeneron Pharmaceuticals, Inc. shares have lost >50% of their value over the past 12 months. Regeneron remains a powerhouse pharma however, despite threats to its key drug Eylea from generics and ...

Shares of Regeneron Pharmaceuticals ( REGN 0.56%), a biotech giant, have been southbound over the past two years as the ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds. On August 4, BMO Capital lifted the price target on the company’s stock ...

Regeneron (REGN) reported $3.75 billion in revenue for the quarter ended September 2025, representing a year-over-year increase of 0.9%. EPS of $11.83 for the same period compares to $12.46 a year ago ...